• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    2/12/24 4:05:34 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNTA alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 2)

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS
    FILED PURSUANT TO RULE 13D-1(b), (c) AND (d)
    AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(b)

     

    Genenta Science S.p.A.
    (Name of Issuer)

     

    Ordinary Shares
    (Title of Class of Securities)

     

    36870W100
    (CUSIP Number)

     

    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1 (b)
      ☐ Rule 13d-1 (c)
      ☒ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     

     
    CUSIP No. 36870W10013GAPage 2 of 4 Pages

     

    1 NAME OF REPORTING PERSON  
      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
      Pierluigi Paracchi  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Italy  
    NUMBER OF 5 SOLE VOTING POWER  
    SHARES  
    BENEFICIALLY   2,294,421  
    OWNED BY 6 SHARED VOTING POWER  
    EACH      
    REPORTING   0  
    PERSON 7 SOLE DISPOSITIVE POWER  
           
        2,294,421  
      8 SHARED DISPOSITIVE POWER  
           
        0  
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      2,294,421  
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
         
         
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
         
      12.6%  
    12 TYPE OF REPORTING PERSON  
         
      IN  

     

    * Based on 18,216,958 ordinary shares outstanding as of December 31, 2023.

     

     
    CUSIP No. 36870W10013GAPage 3 of 4 Pages

     

    Item 1(a). Name of Issuer: Genenta Science S.p.A.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices: Via Olgettina No. 58, 20132 Milan, Italy.
       
    Item 2(a). Name of Person Filing: Pierluigi Paracchi.
       
    Item 2(b). Address of Principal Business Office or if none, Residence: Via Olgettina No. 58, 20132 Milan, Italy.
       
    Item 2(c). Citizenship: Italy
       
    Item 2(d). Title of Class of Securities: Ordinary shares
       
    Item 2(e). CUSIP Number: 36870W100
       
    Item 3. Not Applicable
       
    Item 4. Ownership:

     

      (a)   Amount Beneficially Owned: 2,294,421. Includes 20,513 American depository shares, each representing one ordinary share.
           
      (b)   Percent of Class: 12.6%, based on 18,216,958 ordinary shares outstanding as of December 31, 2023.
           
      (c)   Number of shares as to which such person has:
           
          (i) sole power to vote or to direct the vote: 2,294,421
             
          (ii) shared power to vote or to direct the vote: 0
             
          (iii) sole power to dispose or to direct the disposition of: 2,294,421
             
          (iv) shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class: Not Applicable
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable
       
    Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable
       
    Item 8. Identification and Classification of Members of the Group: Not Applicable
       
    Item 9. Notice of Dissolution of Group: Not Applicable
       
    Item 10. Certification: Not Applicable

     

     
    CUSIP No. 36870W10013GAPage 4 of 4 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 12, 2024
       
      /s/ Pierluigi Paracchi
      Pierluigi Paracchi

     

     

     

    Get the next $GNTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNTA

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

      MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production. This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven exper

      5/7/25 7:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

      MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at "Montalcini Global Biotech Tour" in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta's pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million

      4/15/25 5:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

      MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds. With deep expertise in the biomedical sector, ETB is an established authority in identifying and supporting high-pote

      3/19/25 9:28:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care